An Open-Label Multicenter Phase 1 Study of E7046 in Subjects With Selected Advanced Malignancies
Phase of Trial: Phase I
Latest Information Update: 18 Nov 2016
At a glance
- Drugs E 7046 (Primary)
- Indications Bladder cancer; Breast cancer; Cervical cancer; Colorectal cancer; Head and neck cancer; Liver cancer; Non-small cell lung cancer; Ovarian cancer; Pancreatic cancer; Renal cell carcinoma; Solid tumours; Squamous cell cancer
- Focus Adverse reactions
- Sponsors Eisai Inc
- 09 Aug 2016 Planned End Date changed from 1 Mar 2017 to 1 Sep 2017.
- 09 Aug 2016 Planned primary completion date changed from 1 Feb 2017 to 1 Mar 2017.
- 03 Jun 2016 Trial design has been presented at the 52nd Annual Meeting of the American Society of Clinical Oncology.